Premium Nahrungsergänzungsmittel | artgerecht

Ameloblastoma – Causes, Symptoms and Treatment

Ameloblastoma is a rare, benign but locally aggressive tumor of the jawbone that originates from tooth-forming (odontogenic) epithelial tissue and most commonly affects the lower jaw.

Regular tips about health Regular tips about health

Things worth knowing about "Ameloblastoma"

Ameloblastoma is a rare, benign but locally aggressive tumor of the jawbone that originates from tooth-forming (odontogenic) epithelial tissue and most commonly affects the lower jaw.

What Is an Ameloblastoma?

An ameloblastoma is a rare tumor arising in the jawbone from the enamel organ epithelium – the tissue responsible for forming dental enamel during tooth development. Although it is classified as a benign (non-cancerous) tumor in most cases, it grows in a locally aggressive manner and can cause significant destruction of the jawbone. Malignant transformation, while uncommon, can occur. Ameloblastoma accounts for approximately 1% of all oral tumors and about 10% of all odontogenic (tooth-related) tumors.

Causes and Origin

The exact causes of ameloblastoma are not fully understood. It is believed to arise from remnants of the enamel-forming epithelium that persist in the jaw after tooth development. Factors under discussion include:

Residual enamel organ tissue (dental follicle remnants) within the jawbone
Epithelial linings of jaw cysts (e.g., dentigerous cysts)
Genetic alterations, particularly BRAF gene mutations (V600E mutation), identified in a large proportion of cases
Basal cells of the oral mucosa

Ameloblastoma most commonly presents between the ages of 30 and 60 and affects males and females equally. Approximately 80% of cases involve the mandible (lower jaw), particularly the molar region.

Types of Ameloblastoma

The World Health Organization (WHO) recognizes several distinct subtypes:

Conventional (solid/multicystic) ameloblastoma: The most common form, locally aggressive with a high recurrence rate
Unicystic ameloblastoma: Predominantly affects younger patients, less aggressive, typically presents as a single cyst-like lesion
Extraosseous (peripheral) ameloblastoma: Very rare, arises in the soft tissue of the gingiva rather than the bone
Metastasizing ameloblastoma: Rarest subtype, histologically benign but capable of forming distant metastases
Ameloblastic carcinoma: The malignant variant, exhibiting cytological features of malignancy

Symptoms

Ameloblastoma typically grows slowly and painlessly over many years, which means it is often diagnosed late. Common signs and symptoms include:

Slowly progressive, painless swelling of the jaw or face
Expansion and deformity of the jawbone
Loosening or displacement of teeth
Difficulty swallowing or opening the mouth in larger tumors
Occasional numbness in the jaw or lip region
Incidental finding on dental X-rays

Diagnosis

Diagnosis of ameloblastoma is based on a combination of imaging studies and histological examination:

Imaging

Panoramic radiograph (OPG): Typically reveals a soap-bubble or multilocular radiolucency within the jaw
Computed tomography (CT): Provides detailed assessment of tumor extent and bone destruction
Magnetic resonance imaging (MRI): Useful for evaluating soft tissue involvement

Tissue Analysis

Biopsy with histopathological examination: Confirms the diagnosis by microscopic analysis of tumor tissue
Molecular pathology: Detection of BRAF mutations to guide treatment planning

Treatment

Treatment depends on the tumor subtype, location, and extent of involvement. Given the high recurrence potential of ameloblastoma, radical surgical resection remains the gold standard of care.

Surgical Treatment

Radical resection: Removal of the tumor with adequate margins of healthy bone; the preferred approach for conventional ameloblastoma
Conservative enucleation/curettage: May be considered for unicystic forms, but carries a higher risk of recurrence
Reconstruction: Following major jaw resection, bone reconstruction is commonly performed using autologous bone grafts (e.g., free fibula flap)

Medical and Adjuvant Therapy

In inoperable or recurrent cases with confirmed BRAF V600E mutation, targeted therapy with BRAF inhibitors (e.g., vemurafenib, dabrafenib) may be considered
Radiation therapy and chemotherapy play a limited role in benign ameloblastoma but may be relevant in ameloblastic carcinoma

Follow-Up and Prognosis

The prognosis following complete surgical removal is generally favorable; however, long-term follow-up is essential due to the high risk of recurrence. Recurrences can appear years or even decades after initial treatment. Regular clinical examinations and imaging follow-up (X-ray, CT) are strongly recommended.

References

Wright JM, Vered M. Update from the 4th Edition of the World Health Organization Classification of Head and Neck Tumours: Odontogenic and Maxillofacial Bone Tumors. Head and Neck Pathology, 2017; 11(1): 68–77.
Effiom OA, Ogundana OM, Akinshipo AO, Akintoye SO. Ameloblastoma: current etiopathological concepts and management. Oral Diseases, 2018; 24(3): 307–316.
Brown NA, Betz BL. Ameloblastoma: A Review of Recent Molecular Pathogenetic Discoveries. Biomarkers in Cancer, 2015; 7(Suppl 2): 19–24.

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.

Most read entries

3 Posts in this encyclopedia category